Filing Details
- Accession Number:
- 0001209191-13-047182
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-10-03 16:28:24
- Reporting Period:
- 2013-10-01
- Filing Date:
- 2013-10-03
- Accepted Time:
- 2013-10-03 16:28:24
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1557290 | A Stuart Arbuckle | C/O Vertex Pharmaceuticals Incorporated 130 Waverly St. Cambridge, MA 02139 | Evp\Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2013-10-01 | 3,435 | $75.73 | 48,316 | No | 4 | S | Direct | |
Common Stock | Disposition | 2013-10-01 | 8,982 | $76.49 | 39,334 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 140 | Indirect | 401(k) |
Footnotes
- Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $75.73 (range $75.05 to $75.99).
- Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $76.49 (range $76.03 to $76.85).